BGNE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BGNE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BeiGene's interest expense for the three months ended in Mar. 2024 was $ 0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BeiGene's Operating Income for the three months ended in Mar. 2024 was $ -261 Mil. BeiGene's Interest Expense for the three months ended in Mar. 2024 was $ 0 Mil. GuruFocus does not calculate BeiGene's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for BeiGene's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeiGene Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Interest Expense | Get a 7-Day Free Trial | - | - | -15.76 | - | - |
BeiGene Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Interest Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeiGene (NAS:BGNE) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
BeiGene's Interest Expense for the three months ended in Mar. 2024 was $0 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-261 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $217 Mil.
BeiGene's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
GuruFocus does not calculate BeiGene's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. BeiGene Ltd has enough cash to cover all of its debt. Its financial situation is stable.
Baker Bros. Advisors Lp | director, 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Chan Henry Lee | officer: SVP, General Counsel | 55 CAMBRIDGE PARKWAY, SUITE 700W, CAMBRIDGE MA 02142 |
Julia Aijun Wang | officer: Chief Financial Officer | C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108 |
Lai Wang | officer: Global Head of R&D | C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108 |
Xiaobin Wu | officer: President and GM China | C/O MOURANT OZANNES CRP SVCS CAYMAN LTD, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
Sanders Corazon (corsee) D. | director | C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729 |
Hillhouse Capital Advisors, Ltd. | 10 percent owner | OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006 |
Xiaodong Wang | director | C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
John Oyler | director, 10 percent owner, officer: Chief Executive Office | C/O GENTA INC, 3550 GENERAL ATOMICS CT BLDG 9, SAN DIEGO CA 92121 |
Alessandro Riva | director | C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104 |
Margaret Dugan | director | C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108 |
Jane Huang | officer: CMO, Hematology | C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
Amgen Inc | 10 percent owner | ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320 |
Howard Liang | officer: CFO & CSO | C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
Timothy Yung-cheng Chen | director | LSI LOGIC CORP, 1621 BARBER LANE, MILPITAS CA 95035 |
From GuruFocus
By GuruFocus Research • 11-10-2023
By PRNewswire • 06-30-2023
By Business Wire • 07-21-2023
By GuruFocus Research • 06-21-2023
By Business Wire • 11-08-2023
By Business Wire • 07-10-2023
By Business Wire • 06-27-2023
By Marketwired • 07-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.